# Oneview Healthcare PLC ARBN 610 611 768

# APPENDIX 4D – HALF YEAR REPORT GIVEN TO ASX UNDER LISTING RULE 4.2A.3 FOR THE 6 MONTH PERIOD ENDED 30 JUNE 2016

Item	Contents
1	Details of the reporting period
2	Results for announcement to the market
3	Net tangible assets per security
4	Dividends and distributions
5	Other information

# 1. DETAILS OF THE REPORTING PERIOD

Reporting period: 6 month period ended 30 June 2016

Previous corresponding period: 6 month period ended 30 June 2015

#### 2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

	Up/down	% change	30 June 2016	30 June 2015
	€		€	€
Revenue from ordinary activities	4,150,363	493%	4,991,968	841,605
(Loss) from ordinary activities after tax attributable to members	(1,327,322)	29%	(5,924,819)	(4,597,497)
Net (Loss) for the period attributable to members	(1,327,322)	29%	(5,924,819)	(4,597,497)

The Company has not declared, and does not propose to pay, any dividends for the period ended 30 June 2016.

# Brief explanation of any of the figures reported above necessary to enable the figures to be understood:

Revenue for the six month period to 30 June 2016 was €4,991,968 (2015: €841,605), an increase of 493%. Recurring revenue, which for the period amounted to €511,812 (2015: €302,751), an increase of 69%, continues to grow as the company expands its customer base. During the period, the company continued implementation across the following hospitals or hospital systems:

- Epworth HealthCare comprising 8 hospitals in Melbourne, Australia
- The Sydney Children's Hospital Network at Westmead in Sydney,
- The University of Iowa Children's Hospital in Iowa City

As at 30 June 2016, the Oneview system was live in 1,671 beds with a further 3,291 beds contracted but not yet installed. There were a further 2,836 beds in contract negotiation and 7,439 beds in tender

process. During the period, Oneview announced the signing of a multi-year contract with NYU Langone Medical Center (a leading academic teaching hospital in Manhattan) to deploy Oneview's software initially at its 374 bed state-of-the-art facility, Helen L. and Martin S Kimmel Pavilion in New York. The contract provides for the further roll-out of Oneview's software across 2,000 end points (equivalent to an estimated 1,000 beds) across other NYU facilities. Oneview also announced a number of US based proof of concept implementation projects with three separate hospital systems which the directors expect to convert to full scale hospital implementations in the second half of 2016. The company continues to have a strong pipeline of new business opportunities across the four territories in which the group currently operates.

Following the company's IPO, the business has continued to invest in attracting world-class employees across each of its primary office locations and has over doubled the headcount to 104 personnel as at 30 June 2016 from 51 at 30 June 2015. The growth in headcount has primarily been in the areas of sales, implementation and research and development. To support the significant planned further US expansion the company recently announced the opening of a new US headquarters based in Chicago which is scheduled to open in September.

For further information, please see the Directors Report in the Interim Financial Results.

# 3. NET TANGIBLE ASSETS PER SECURITY

	6 month period	6 month period	% change	
	ended 30 June 2016	ended 30 June 2015		
Net tangible assets per security	€0.81	€0.41	98	3%

Net tangible assets are defined as the net assets of Oneview Healthcare Plc less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

On 17 March 2016, the company listed on the Australian Securities Exchange and issued 17,430,340 new shares bringing the total number of issued shares to 54,296,700.

# 4. DIVIDENDS AND DISTRIBUTIONS

The Company did not pay any distributions during the 6 month period ended 30 June 2016. The Company has not declared any distributions for the 6 month period ended 30 June 2016.

# 5. OTHER INFORMATION

Details of entities over which control has been gained or lost during the 6 months to 30 June 2016: N/A

Details of any dividend or distribution reinvestment plans in operation: N/A

Details of associates and joint venture entities: N/A

The interim financial statements for the half year ended 30 June 2016 forms part of and should be read in conjunction with this half year report (Appendix 4D). The unaudited condensed consolidated financial report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union.

Any other information required pursuant to ASX Listing Rule 4.2A not contained in this Appendix 4D is found in the attached Interim Financial Report.